-
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
-
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
